Navigation Links
Stem cells act through multiple mechanisms to benefit mice with neurodegenerative disease

the mice a simple oral drug that permitted the amount of enzyme provided by the engrafted stem cells to work even more efficiently by presenting them with a smaller burden of material to metabolize. The lifespan of the mice doubled. (Neither treatment could work as effectively on its own. In fact, the effect was more than simply additive). This was a demonstration that stem cell efficacy could be enhanced even without the need for genetic engineering. (The drug, a glycosphingolipid biosynthesis inhibitor, is in a class of compounds called "substrate reduction therapy" drugs.) This part of the study not only represented the first "multidisciplinary" use of stem cells against a degenerative disease, but also highlighted the fact that, in the future, the most successful therapies - including those employing stem cells -- will likely invoke the use of multiple strategies in concert. Indeed, the stem cell may be the "glue" that ultimately holds these therapies together in an effective manner by virtue of its fundamental biology.

The researchers then sought to extend their insights to the use of human stem cells - either stem cells turned into neural progenitors from human embryonic stem cells - or isolated directly from the nervous system (called "adult" stem cells to distinguish them from embryonic stem cells even though they are taken from developing brain tissue). Both types of human stem cells were actually somewhat more effective than the mouse neural stem cells. And, they were equally as good as each other - in the first head-to-head comparison ever done between embryonic and "adult" stem cells, although the embryonic stem cells were somewhat easier to "scale up" into large quantities. Both types of human stem cells invoked the same range of multiple, collaborative mechanisms. Neither type of human stem cell created tumors, deformation, a worsening of symptoms, or gave rise to inappropriate cells types. Neither cell type was rejected by the immune sy
'"/>

Source:Burnham Institute


Page: 1 2 3 4 5

Related biology news :

1. Wisconsin scientists grow critical nerve cells
2. Spleen may be source of versatile stem cells
3. Researchers discover way to make cells in the eye sensitive to light
4. Priming embryonic stem cells to fulfill their promise
5. Lack of enzyme turns fat cells into fat burners
6. Poor prenatal nutrition permanently damages function of insulin-producing cells in the pancreas
7. Elusive HIV shape change revealed; Key clue to how virus infects cells
8. Mouse brain cells rapidly recover after Alzheimers plaques are cleared
9. Enzyme allows B cells to resist death, leading to leukemia
10. Scientists rid stem cell culture of key animal cells
11. Genetically modified natural killer immune cells attack, kill leukemia cells
Post Your Comments:
(Date:12/5/2014)... Dec. 4, 2014  Tute Genomics, a leader in ... in Series A1 funding led by UK-based Eurovestech. Peak ... in the investment round. "We are at ... adopts next-generation sequencing and seeks new approaches for the ... Robison , MD MBA, and CEO of Tute Genomics. ...
(Date:11/21/2014)... November 18, 2014 According to ... by Systems (Video, RFID, Access Control, Intrusion Detection, Parking ... Banks, Government), Component Service Geography - Global Forecasts to ... is projected to be around $25 Billion in 2014 ... growing at a CAGR of 8.69%. Browse ...
(Date:11/21/2014)... 2014   Atmel® Corporation (NASDAQ: ... touch technology solutions, today launched the industry,s first family ... widest V cc range from 1.7V to 5.5V. ... I 2 C bus communication speeds, and are available ... them ideal for consumer, industrial, computer, and medical applications. ...
Breaking Biology News(10 mins):Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4
... Neagh, has lost more than three quarters of its overwintering ... study by Quercus, Northern Ireland,s Centre for Biodiversity and Conservation ... lake for the winter months has dropped from 100,000 to ... research, published in the journal Freshwater Biology , found ...
... Munich, November 13, 2013 - Elsevier, a world-leading provider ... is pleased to announce the launch of the new ... aim of Photoacoustics is to publish original ... field of photoacoustics (optoacoustics) and thermoacoustics. Research in this ...
... , Nov. 13, 2013  Baxter International Inc. today announced ... trial of BAX 855, an investigational extended half-life, recombinant ... trial is aimed at assessing the efficacy of the ... prophylaxis and on-demand treatment schedules, and will also evaluate ...
Cached Biology News:Largest lake in Britain and Ireland has lost three-quarters of winter water birds 2Elsevier launches new open access journal: Photoacoustics 2Baxter Completes Enrollment In Phase III Clinical Trial Of BAX 855, Extended Half-life Recombinant FVIII For Hemophilia A 2Baxter Completes Enrollment In Phase III Clinical Trial Of BAX 855, Extended Half-life Recombinant FVIII For Hemophilia A 3Baxter Completes Enrollment In Phase III Clinical Trial Of BAX 855, Extended Half-life Recombinant FVIII For Hemophilia A 4Baxter Completes Enrollment In Phase III Clinical Trial Of BAX 855, Extended Half-life Recombinant FVIII For Hemophilia A 5Baxter Completes Enrollment In Phase III Clinical Trial Of BAX 855, Extended Half-life Recombinant FVIII For Hemophilia A 6
(Date:12/22/2014)... 22, 2014  ( www.competitivehealth.com ) — Competitive Health ... bill review and advocacy service, has signed an agreement ... Savings discount health services marketplace. 63% of ... than they expected to pay. As part of an ... WellCard Savings is pleased to offer medical bill review ...
(Date:12/19/2014)... 2014 Charm Sciences is pleased to ... Detection of Aflatoxin M1 in raw commingled milk is ... party validation. The peer reviewed report of the validation ... for Agricultural and Fisheries Research (ILVO-T&V) has been published ... B1, the most toxic aflatoxin and a known carcinogen, ...
(Date:12/19/2014)... , Dec. 19, 2014 Decision Resources Group ... grow at a 12 percent compound annual growth rate ... the aging population and the increasing adoption of dental ... will also spur demand for dental biomaterials ... implant and periodontal treatments. Other key findings ...
(Date:12/19/2014)... Ed Bilsky, Ph.D., vice president for ... Excellence in the Neurosciences (CEN), and professor of pharmacology ... as a member of the prestigious Dana Alliance for ... Maine to receive this honor. , The Dana ... the Dana Foundation. Its mission is to advance ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 2UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 3
... a provider of electronic parts catalogs and related technology ... and record net income for the fiscal year ended July ... million, a 2% increase from revenues of $13.4 million in ... $0.32 per diluted share, from operating income of $1.3 million ...
... and Milwaukee officials on Wednesday announced plans to launch ... network accessible to all residents. , ,The Milwaukee Wireless ... large city in America, built at no cost to ... , ,"This initiative constitutes a multi-million dollar private investment, ...
... is critical to any new medical technology or treatment's ... as determinative. , ,"Coverage" is whether there will ... is how much payment there will be if there ... analyses in their evaluation of new products and, depending ...
Cached Biology Technology:Milwaukee announces citywide wireless initiative 2On track with the FDA -- But what about your coverage and reimbursement strategy? 2On track with the FDA -- But what about your coverage and reimbursement strategy? 3On track with the FDA -- But what about your coverage and reimbursement strategy? 4
DEAD (Asp-Glu-Ala-Asp) box polypeptide 5...
...
RayBio L Series 507: RayBio Label-based Antibody Array I (1 glass slide with 2 subarrays) Class: Antibody Array Products Product Group: Antibody Array...
Rat CXCL7/Thymus Chemokine-1 DuoSet Economy Pack, 45 Plate...
Biology Products: